Anthropic goes public next week despite the AI slump: the market debates what the bet is worth

By Yahoo Finance (citing the Wall Street Journal) · November 9, 2026.

Anthropic is aiming to debut on the stock market this coming Thursday or Friday, the Wall Street Journal reported on Monday, citing people familiar with the matter. The company would list on the Nasdaq under the ticker ANT. It is sticking to the timetable despite recent volatility in AI stocks and pushback from some investors on the expected valuation.

According to the WSJ, Anthropic has meetings with key investors this week. It is expected to publish the offering's price range in a regulatory filing early in the week. That filing should also state how many shares it will sell and could disclose commitments from large investors to participate. The lead banks are Goldman Sachs and Morgan Stanley.

Valuation is the sticking point. Until last week, a figure of about $1.5 trillion was being floated (1.5 “billones” on the Spanish scale). After Thursday's sharp sell-off, in which Nasdaq companies collectively lost $2.5 trillion in market capitalization, some large investors are pushing it lower. The roughly $2 trillion figure discussed months ago looks increasingly hard to reach. The market has recovered somewhat since then, but doubts persist about the enormous investment in AI infrastructure and about when (and whether) it will pay off.

The WSJ adds that Anthropic could still postpone the deal if the market worsens. But abandoning the timetable now would send an awkward signal about investor appetite for large AI IPOs.

**Our take.** What matters is not the exact valuation at which Anthropic lists, but that it is choosing to go public at the sector's lowest point in sentiment. That insistence says something: the company would rather set a price with a nervous market than let the “bubble” narrative take hold while it waits. It is a bet on certainty of capital over maximum valuation.

For the sector, this deal works as a barometer. If the offering goes well, even at a discount, it will validate that demand for frontier AI is real and not just private-round euphoria. If it falters, the blow to confidence would reach the whole ecosystem, from the labs to the chip and data center suppliers.

There is an underlying tension that deserves attention. A publicly traded AI company will have to answer quarter by quarter on revenue and margins, in a business where compute spending is colossal. That can impose discipline, but also pressure to monetize in the short term, just when safety and long-term research demand patience. How that tension is governed will need watching, especially at a company that has defined itself by its focus on safety.

In the long run, the thesis we hold does not depend on a share price: funding the compute capacity needed to accelerate medical science and abundance still requires massive capital, and public markets are one way to obtain it. That this capital arrives at a reasonable, rather than inflated, price is actually good news for the sector's sustainability. A valuation correction hurts in the short term, but it prevents a bubble from dragging down projects that are genuinely worthwhile.

Caveat: all of the above is based on information attributed to anonymous WSJ sources. The price range, number of shares and final date are not confirmed until the official filing is published.